Baxter International Inc.

NYQ: BAX
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Baxter International Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get BAX Z-Score →

About Baxter International Inc.

Healthcare Medical Instruments & Supplies
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

📊 Fundamental Analysis

Baxter International Inc. demonstrates a profit margin of -8.5%, which is below the sector average, suggesting competitive pressure.

The company recently reported 8.0% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is -13.7%, which indicates that capital utilization is currently under pressure.

At a current price of $17.15, BAX currently trades near the bottom of its 52-week range (8%), indicating potential value or weakness (Range: $15.73 - $32.68).

🏥 Financial Health

🔴 Profit Margin Weak
🔴 Debt/Equity Elevated
⚠️ Revenue Growth Moderate
🔴 Return on Equity Weak
Beta (Risk) Low Volatility

Key Financials

Market Cap
$8.85B
Trailing P/E
--
Forward P/E
8.47
Beta (5Y)
0.62
52W High
$32.68
52W Low
$15.73
Avg Volume
9.65M
Day High
Day Low
Get BAX Z-Score on Dashboard 🚀